Opus Genetics, Inc. (IRD)vsBeiGene, Ltd. (ONC)
IRD
Opus Genetics, Inc.
$4.75
+5.32%
HEALTHCARE · Cap: $312.34M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 37538% more annual revenue ($5.34B vs $14.20M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
IRD
Avoid17
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IRD.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
IRD profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
IRD carries more volatility with a beta of 0.59 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 17/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is an innovative biotechnology company specializing in gene therapies for rare retinal diseases that impact vision. Leveraging cutting-edge research and proprietary gene-editing technologies, Opus aims to fulfill significant unmet medical needs through transformative solutions that restore sight. With a dedicated focus on ocular health, the company is positioned as a frontrunner in the biotech industry, appealing to investors interested in pioneering healthcare advancements. Supported by ongoing clinical trials and strategic collaborations, Opus Genetics is well-equipped to improve patient outcomes while generating substantial value for its stakeholders.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?